WO2001083462A1 - Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel - Google Patents
Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel Download PDFInfo
- Publication number
- WO2001083462A1 WO2001083462A1 PCT/EP2001/004278 EP0104278W WO0183462A1 WO 2001083462 A1 WO2001083462 A1 WO 2001083462A1 EP 0104278 W EP0104278 W EP 0104278W WO 0183462 A1 WO0183462 A1 WO 0183462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- nitrogen
- general formula
- group
- formula
- Prior art date
Links
- 0 CC(C=C*(C=C1N2)O)=C1OCC2=O Chemical compound CC(C=C*(C=C1N2)O)=C1OCC2=O 0.000 description 6
- WVNMLOGVAVGQIT-UHFFFAOYSA-N CC[n]1c(cccc2)c2nc1 Chemical compound CC[n]1c(cccc2)c2nc1 WVNMLOGVAVGQIT-UHFFFAOYSA-N 0.000 description 1
- QPQFCEJSBLXSID-UHFFFAOYSA-N CC[n]1nc(-c(cc2)ccc2OC)nc1 Chemical compound CC[n]1nc(-c(cc2)ccc2OC)nc1 QPQFCEJSBLXSID-UHFFFAOYSA-N 0.000 description 1
- GYVGXEWAOAAJEU-UHFFFAOYSA-N Cc(cc1)ccc1N(C)C Chemical compound Cc(cc1)ccc1N(C)C GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 1
- CHLICZRVGGXEOD-UHFFFAOYSA-N Cc(cc1)ccc1OC Chemical compound Cc(cc1)ccc1OC CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- H—ELECTRICITY
- H03—ELECTRONIC CIRCUITRY
- H03F—AMPLIFIERS
- H03F2200/00—Indexing scheme relating to amplifiers
- H03F2200/331—Sigma delta modulation being used in an amplifying circuit
Definitions
- the present invention relates to new betamimetics of the general formula
- radicals R ⁇ and R2 can have the meanings given in the claims and in the description, processes for their preparation and their use as medicaments.
- Betamimetics ( ⁇ -adrenergic substances) are known from the prior art. They can be used in a variety of therapeutic areas.
- betamimetics which are characterized by a longer duration of action and can therefore be used for the production of medicaments with a longer activity.
- the present invention relates to compounds of the general
- R3 benzyl which may optionally be substituted by methoxy;
- R 4 is hydrogen or
- R3 and R 4 together form a -CO-CH2-O- bridge, the carbonyl group of this bridge being bound to the nitrogen,
- Preferred compounds of general formula 1 are those in which
- R1 a remainder selected from
- R5 dimethylamino, methoxy or butoxy
- X is a nitrogen or a carbon
- R 6 if X is nitrogen methoxyphenyl or if X is carbon is a fused phenyl ring which is also linked to X.
- R3 BBeennzzyyll that c can optionally be substituted by methoxy
- R4 is hydrogen
- X is nitrogen or carbon
- R 6 if X is nitrogen methoxyphenyl or if X is carbon is a fused phenyl ring which is also linked to X.
- the invention relates to the respective compounds of the formula optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates and in the form of the free bases or the corresponding acid addition salts with pharmacologically acceptable acids such as, for example, acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid - or organic acids - such as Acetic, oxalic, fumaric, diglycolic acid or methanesulfonic acid.
- pharmacologically acceptable acids such as, for example, acid addition salts with hydrohalic acids - for example hydrochloric or hydrobromic acid - or organic acids - such as Acetic, oxalic, fumaric, diglycolic acid or methanesulfonic acid.
- the salts of hydrochloric acid, methanesulfonic acid and acetic acid are particularly preferred according to the invention.
- Example 3 1 -r3- (4-methoxybenzylamino) -4-hydroxyphenyl-2- [4- (1 -benzimidazoIvD- 2-methyl-2-butylamino1ethanol:
- the compounds of general formula 1 are distinguished by a wide range of possible uses in the therapeutic field. Emphasis should be given to those uses for which the compounds of the formula according to the invention can preferably be used as beta-mimetics due to their pharmaceutical activity. These include, for example, the therapy of bronchial asthma (sagging of the bronchial muscle), the treatment of the inflammatory component in COPD, the inhibition of premature contractions in obstetrics (tocolysis), the restoration of the sinus rhythm in the heart in the case of atrio-ventricular block and the elimination of bradycal cardiac arrhythmias (Antiarrhythmic), therapy of circulatory shock (vasodilation and increase in cardiac output) as well as the treatment of itching and inflammation of the skin.
- bronchial asthma sagging of the bronchial muscle
- the treatment of the inflammatory component in COPD the inhibition of premature contractions in obstetrics (tocolysis)
- the restoration of the sinus rhythm in the heart in the case of atrio-ventricular block and the elimination of
- the compounds of the general formula _ can be used alone or in combination with other active compounds of the formula according to the invention. If appropriate, the compounds of the general formula ⁇ can also be used in combination with other pharmacologically active compounds. These are in particular anticholinergics, possibly other betamimetics, antiallergics, PAF antagonists, leukotriene antagonists and steroids, and combinations of active substances thereof.
- anticholinergics examples include ipratropium bromide, oxitropium bromide and, in particular, tiotropium bromide.
- Pharmaceutical combinations which contain the tiotropium bromide as a further active ingredient in addition to the compounds of the formula 1 according to the invention are particularly preferred according to the invention. This combination is particularly important in the treatment of asthma or COPD, especially COPD.
- Suitable forms of application for applying the compounds of the formula 1 are, for example, tablets, capsules, suppositories, solutions, etc.
- the proportion of the pharmaceutically active compound (s) should in each case be in the range from 0.05 to 90% by weight, preferably 0.1 to 50 % By weight of the total composition.
- Corresponding tablets can be mixed, for example, by mixing the active ingredient (s) with known auxiliaries, for example inert diluents, such as calcium carbonate, calcium phosphate or milk sugar, and disintegrants
- the tablets can also consist of several layers.
- coated tablets can be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
- the core can also consist of several layers.
- the coated tablet shell can also consist of several layers in order to achieve a depot effect, it being possible to use the auxiliaries mentioned above for the tablets.
- Juices of the active substances or combinations of active substances according to the invention can additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract. They can also contain suspending aids or thickeners, such as sodium carboxymethyl cellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or protective agents, such as p-hydroxybenzoates.
- Solutions are used in the usual way, e.g. with the addition of isotonants, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, if appropriate using emulsifiers and / or dispersants, where, for example, when using water as a diluent, organic solvents can optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection bottles or ampoules or infusion bottles.
- the capsules containing one or more active ingredients or combinations of active ingredients can be produced, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatin capsules.
- Suitable suppositories can be produced, for example, by mixing them with carriers, such as neutral fats or polyethylene glycol or its derivatives.
- auxiliary substances include water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. peanut or sesame oil), monofunctional or polyfunctional alcohols (e.g. ethanol or glycerin), carriers such as e.g. natural stone flours (e.g. kaolins, clays, talc, chalk) synthetic stone flours (e.g. highly disperse silicic acid and silicates), sugar (e.g. cane, milk and dextrose) emulsifiers (e.g. lignin, sufite liquor, methyl cellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. Magnesium stearate, talc, stearic acid and sodium lauryl sulfate) mentioned.
- paraffins e.g. petroleum fractions
- oils of vegetable origin e.g. peanut or sesame oil
- monofunctional or polyfunctional alcohols e.
- the application is carried out in the usual way, preferably by inhalation in the treatment of asthma or COPD.
- the tablets can of course also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned.
- Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
- the active ingredients can be mixed with various flavor enhancers or colorants.
- the dosage of the compounds according to the invention is of course highly dependent on the type of application and the disease to be treated.
- the compounds of formula 1 When administered by inhalation, the compounds of formula 1 are highly effective even at doses in the ⁇ g range. Even above the ⁇ g range, the compounds of formula 1 can be used expediently. The dosage can then be in the gram range, for example.
- the finely ground active ingredient, milk sugar and part of the corn starch are mixed together.
- the mixture is sieved, whereupon it is moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
- the granules, the rest of the corn starch and the magnesium stearate are sieved and mixed together.
- the mixture is compressed into tablets of a suitable shape and size.
- the finely ground active ingredient, part of the corn starch, milk sugar, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is sieved and processed with the rest of the corn starch and water to form a granulate which is dried and sieved.
- the sodium carboxymethyl starch and the magnesium stearate are added, and the mixture is mixed and compressed into tablets of a suitable size.
- the active ingredient is dissolved in water at its own pH or, if appropriate, at pH 5.5 to 6.5, and sodium chloride is added as an isotonic agent.
- the solution obtained is filtered pyrogen-free and the filtrate is filled into ampoules under aseptic conditions, which are then sterilized and sealed.
- the ampoules contain 5 mg, 25 mg and 50 mg of active ingredient.
- Sorbitan trioleate 0.1 monofluorotrichloromethane
- Difluorodichloromethane 2 3 ad 100
- the suspension is filled into a conventional aerosol container with a metering valve. 50 ⁇ l of suspension are preferably dispensed per actuation. If desired, the active ingredient can also be dosed in higher amounts (for example 0.02% by weight).
- This solution can be prepared in the usual way.
- the inhalable powder is prepared in the usual way by mixing the individual components.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0300832A HUP0300832A2 (hu) | 2000-04-27 | 2001-04-14 | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
KR1020027014388A KR20020093083A (ko) | 2000-04-27 | 2001-04-14 | 신규한 완효성 베타모사체, 이의 제조방법 및 약제로서의이의 용도 |
JP2001580891A JP2003533448A (ja) | 2000-04-27 | 2001-04-14 | 新規持続性ベータ擬似剤、その製造方法及びその医薬としての使用 |
CA002405745A CA2405745A1 (en) | 2000-04-27 | 2001-04-14 | New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments |
EP01929560A EP1305300A1 (de) | 2000-04-27 | 2001-04-14 | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
EA200201056A EA200201056A1 (ru) | 2000-04-27 | 2001-04-14 | Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств |
BR0110331-8A BR0110331A (pt) | 2000-04-27 | 2001-04-14 | Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos |
MXPA02010179A MXPA02010179A (es) | 2000-04-27 | 2001-04-14 | Nuevos betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos. |
IL15214001A IL152140A0 (en) | 2000-04-27 | 2001-04-14 | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
EEP200200602A EE200200602A (et) | 2000-04-27 | 2001-04-14 | Pikatoimelised beetamimeetikumid, meetod nende valmistamiseks ja nende kasutamine ravimitena |
AU56293/01A AU5629301A (en) | 2000-04-27 | 2001-04-14 | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
SK1538-2002A SK15382002A3 (sk) | 2000-04-27 | 2001-04-14 | Betamimetiká, farmaceutický prostriedok s ich obsahom a ich použitie |
NZ522677A NZ522677A (en) | 2000-04-27 | 2001-04-14 | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
BG107120A BG107120A (en) | 2000-04-27 | 2002-09-18 | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
NO20025133A NO20025133L (no) | 2000-04-27 | 2002-10-25 | Nye, lengevirkende betamimetika, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP00-3424 | 2000-04-27 | ||
ECSP003424 ECSP003424A (es) | 2000-04-27 | 2000-04-27 | NUEVAS COMPOSICIONES DE MEDICAMENTOS A BASE DE COMPUESTOS ANTICOLINERGICAMENTE ACTIVOS Y ß-MIMETICOS |
DE2000151318 DE10051318A1 (de) | 2000-10-17 | 2000-10-17 | Neu, langwirksame Betamimetika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10051318.2 | 2000-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001083462A1 true WO2001083462A1 (de) | 2001-11-08 |
Family
ID=40317111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/004278 WO2001083462A1 (de) | 2000-04-27 | 2001-04-14 | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
Country Status (23)
Country | Link |
---|---|
US (2) | US20020022625A1 (de) |
EP (1) | EP1305300A1 (de) |
JP (1) | JP2003533448A (de) |
KR (1) | KR20020093083A (de) |
CN (1) | CN1426401A (de) |
AR (1) | AR035637A1 (de) |
AU (1) | AU5629301A (de) |
BG (1) | BG107120A (de) |
BR (1) | BR0110331A (de) |
CA (1) | CA2405745A1 (de) |
CZ (1) | CZ20023537A3 (de) |
EA (1) | EA200201056A1 (de) |
EE (1) | EE200200602A (de) |
HR (1) | HRP20020845A2 (de) |
HU (1) | HUP0300832A2 (de) |
IL (1) | IL152140A0 (de) |
MX (1) | MXPA02010179A (de) |
NO (1) | NO20025133L (de) |
NZ (1) | NZ522677A (de) |
PL (1) | PL362868A1 (de) |
SK (1) | SK15382002A3 (de) |
WO (1) | WO2001083462A1 (de) |
YU (1) | YU79502A (de) |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6670376B1 (en) | 2001-11-13 | 2003-12-30 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
WO2004033412A1 (de) * | 2002-10-04 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue betamimetika mit verlängerter wirkungsdauer, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2004046083A1 (de) * | 2002-11-15 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue dihydroxy-methyl-phenyl-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2005070908A1 (de) * | 2004-01-23 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Neue lang wirksame beta-2-agonisten, und deren verwendung als arzneimittel |
WO2005077361A1 (de) * | 2004-02-14 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel |
EP1577306A1 (de) * | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
US6949568B2 (en) | 2001-11-13 | 2005-09-27 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6951888B2 (en) | 2002-10-04 | 2005-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions |
WO2005102349A1 (de) | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
WO2005102350A1 (de) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Benzoxazine zur behandlung von atemwegserkrankungen |
WO2005111004A1 (de) * | 2004-05-14 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Neue langwirksame bronchodilatoren zur behandlung von atemwegserkrankungen |
WO2006056471A1 (en) | 2004-11-29 | 2006-06-01 | Novartis Ag | 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity |
WO2006108643A2 (en) | 2005-04-14 | 2006-10-19 | Novartis Ag | Organic compounds |
WO2007042468A2 (de) * | 2005-10-10 | 2007-04-19 | Boehringer Ingelheim International Gmbh | Aerosolformulierung für die inhalation von betaagonisten |
US7244728B2 (en) | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
WO2007121920A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
JP2007537187A (ja) * | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
WO2008017638A1 (de) * | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2008017637A1 (de) | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
US7405232B2 (en) | 2004-02-14 | 2008-07-29 | Boehringer Ingelheim International Gmbh | Long acting beta-2 agonists and their use as medicaments |
WO2008097673A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
US7423036B2 (en) | 2005-02-19 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Long-acting betamimetics for the treatment of respiratory complaints |
US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
EP2206499A1 (de) | 2004-11-02 | 2010-07-14 | Novartis AG | Quinuclidinderivate und ihre verwendung als muscarinic m3 rezeptor antagonisten |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
EP2280006A1 (de) | 2005-08-08 | 2011-02-02 | Pulmagen Therapeutics (Synergy) Limited | Pharmazeutische zusammensetzung zum inhalieren enthaltend einen oxazol oder thiazol m3-muscarinrezeptor-antagonisten |
EP2279777A2 (de) | 2007-01-10 | 2011-02-02 | Irm Llc | Kanalaktivierende Proteasehemmer und deren Zusammensetzungen |
EP2281819A1 (de) | 2004-01-21 | 2011-02-09 | Novartis AG | Benzimidazol- oder Benzoxazol-derivate |
EP2281813A1 (de) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]Hept-7-Ylamin Derivate und deren Verwendung |
EP2286813A2 (de) | 2006-01-31 | 2011-02-23 | Novartis AG | Verwendung von Naphthyridin-Derivaten als Heilmittel |
EP2292619A1 (de) | 2004-10-22 | 2011-03-09 | Novartis AG | Purinderivate und ihre Verwendung als Adenosin A-2A Rezeptor Agonisten |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
WO2011051672A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Azaindole derivatives |
WO2011051671A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Aminopyridine derivatives as kallikrein inhibitors |
WO2011051673A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Aminothiazole derivatives useful as klk1 inhibitors |
EP2332933A1 (de) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial Natrium-Kanal Inhibitoren |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
WO2011098799A2 (en) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2011098801A1 (en) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Inflammatory disease treatment |
WO2011113894A1 (en) | 2010-03-19 | 2011-09-22 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012035158A1 (en) | 2010-09-17 | 2012-03-22 | Novartis Ag | Pyrazine derivatives as enac blockers |
EP2444120A1 (de) | 2007-12-10 | 2012-04-25 | Novartis AG | Spirocyclische Amiloride Analoga als ENac Blocker |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2532677A1 (de) | 2005-10-21 | 2012-12-12 | Novartis AG | Menschliche Antikörper gegen IL13 und therapeutische Verwendungen |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
WO2013140319A1 (en) | 2012-03-19 | 2013-09-26 | Novartis Ag | Crystalline form of a succinate salt |
WO2014132220A1 (en) | 2013-03-01 | 2014-09-04 | Novartis Ag | Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
EP3603634A1 (de) | 2004-05-18 | 2020-02-05 | Novartis AG | Pharmazeutische zusammensetzung enthaltend glykopyrrolat und einen beta2-adrenoceptor antagonisten |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
WO2021038426A1 (en) | 2019-08-28 | 2021-03-04 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
WO2021152488A1 (en) | 2020-01-29 | 2021-08-05 | Novartis Ag | Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
DE10349850C5 (de) | 2003-10-25 | 2011-12-08 | Clariant Produkte (Deutschland) Gmbh | Kaltfließverbesserer für Brennstofföle pflanzlichen oder tierischen Ursprungs |
TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
US20050272726A1 (en) * | 2004-04-22 | 2005-12-08 | Boehringer Ingelheim International Gmbh | Novel medicaments for the treatment of respiratory diseases |
US7307076B2 (en) * | 2004-05-13 | 2007-12-11 | Boehringer Ingelheim International Gmbh | Beta agonists for the treatment of respiratory diseases |
EP1595873A1 (de) * | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
MXPA06013916A (es) * | 2004-06-03 | 2007-03-07 | Theravance Inc | Agosnistas del receptor adrenergico beta2 de diamina. |
JP2008507532A (ja) * | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
EP0321864A2 (de) * | 1987-12-19 | 1989-06-28 | Boehringer Ingelheim Kg | Neue Ammoniumverbindungen, ihre Herstellung und Verwendung |
EP0341559A2 (de) * | 1988-05-06 | 1989-11-15 | Boehringer Ingelheim Kg | Synergistische Kombinationen und ihre Verwendung als Therapeutika |
WO1991000088A1 (fr) * | 1989-06-23 | 1991-01-10 | Boehringer Ingelheim France | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants |
EP0455155A1 (de) * | 1990-05-04 | 1991-11-06 | Boehringer Ingelheim Vetmedica Gmbh | Enantiomerentrennung von Cimaterol |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US115681A (en) * | 1871-06-06 | Improvement in water-wheels | ||
US133010A (en) * | 1872-11-12 | Improvement in car-springs | ||
US648621A (en) * | 1899-07-24 | 1900-05-01 | James M Hooper | Strait-jacket. |
DE2540633A1 (de) * | 1975-09-12 | 1977-04-28 | Boehringer Sohn Ingelheim | Neue quartaere n-beta-substituierte benzilsaeure-n-alkyl-nortropinester und verfahren zu deren herstellung |
DE3211185A1 (de) * | 1982-03-26 | 1983-09-29 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue quartaere 6,11-dihydro-dibenzo-(b,e)-thiepin-11-n-alkyl- norscopinether und verfahren zu deren herstellung |
DE3215493A1 (de) * | 1982-04-26 | 1983-11-03 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue zwischenprodukte, verfahren zu ihrer herstellung und ihre verwendung |
US5223614A (en) * | 1987-12-19 | 1993-06-29 | Boehringer Ingelheim Gmbh | New quaternary ammonium compounds, their preparation and use |
US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
US5770738A (en) * | 1992-03-05 | 1998-06-23 | Boehringer Ingelheim Kg | Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions |
DE19515625C2 (de) * | 1995-04-28 | 1998-02-19 | Boehringer Ingelheim Kg | Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern |
US6506900B1 (en) * | 2001-01-31 | 2003-01-14 | Boehringer Ingelheim Pharma Ag | Process for preparing a scopine ester intermediate |
US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
-
2001
- 2001-04-14 PL PL01362868A patent/PL362868A1/xx not_active Application Discontinuation
- 2001-04-14 WO PCT/EP2001/004278 patent/WO2001083462A1/de not_active Application Discontinuation
- 2001-04-14 EP EP01929560A patent/EP1305300A1/de not_active Withdrawn
- 2001-04-14 KR KR1020027014388A patent/KR20020093083A/ko not_active Application Discontinuation
- 2001-04-14 CN CN01808610A patent/CN1426401A/zh active Pending
- 2001-04-14 BR BR0110331-8A patent/BR0110331A/pt not_active Expired - Fee Related
- 2001-04-14 SK SK1538-2002A patent/SK15382002A3/sk not_active Application Discontinuation
- 2001-04-14 NZ NZ522677A patent/NZ522677A/en unknown
- 2001-04-14 EA EA200201056A patent/EA200201056A1/ru unknown
- 2001-04-14 HU HU0300832A patent/HUP0300832A2/hu unknown
- 2001-04-14 EE EEP200200602A patent/EE200200602A/xx unknown
- 2001-04-14 CZ CZ20023537A patent/CZ20023537A3/cs unknown
- 2001-04-14 AU AU56293/01A patent/AU5629301A/en not_active Abandoned
- 2001-04-14 MX MXPA02010179A patent/MXPA02010179A/es unknown
- 2001-04-14 IL IL15214001A patent/IL152140A0/xx unknown
- 2001-04-14 CA CA002405745A patent/CA2405745A1/en not_active Abandoned
- 2001-04-14 YU YU79502A patent/YU79502A/sh unknown
- 2001-04-14 JP JP2001580891A patent/JP2003533448A/ja active Pending
- 2001-04-18 US US09/836,462 patent/US20020022625A1/en not_active Abandoned
- 2001-04-27 AR ARP010101985A patent/AR035637A1/es active Pending
-
2002
- 2002-09-18 BG BG107120A patent/BG107120A/xx active Pending
- 2002-10-24 HR HR20020845A patent/HRP20020845A2/hr not_active Application Discontinuation
- 2002-10-25 NO NO20025133A patent/NO20025133L/no not_active Application Discontinuation
-
2005
- 2005-02-08 US US11/053,514 patent/US20050137242A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
EP0321864A2 (de) * | 1987-12-19 | 1989-06-28 | Boehringer Ingelheim Kg | Neue Ammoniumverbindungen, ihre Herstellung und Verwendung |
EP0341559A2 (de) * | 1988-05-06 | 1989-11-15 | Boehringer Ingelheim Kg | Synergistische Kombinationen und ihre Verwendung als Therapeutika |
WO1991000088A1 (fr) * | 1989-06-23 | 1991-01-10 | Boehringer Ingelheim France | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants |
EP0455155A1 (de) * | 1990-05-04 | 1991-11-06 | Boehringer Ingelheim Vetmedica Gmbh | Enantiomerentrennung von Cimaterol |
Cited By (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125892B2 (en) | 2001-11-13 | 2006-10-24 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6949568B2 (en) | 2001-11-13 | 2005-09-27 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6670376B1 (en) | 2001-11-13 | 2003-12-30 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
WO2004033412A1 (de) * | 2002-10-04 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue betamimetika mit verlängerter wirkungsdauer, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US6951888B2 (en) | 2002-10-04 | 2005-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions |
US8044046B2 (en) | 2002-11-15 | 2011-10-25 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
WO2004046083A1 (de) * | 2002-11-15 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue dihydroxy-methyl-phenyl-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US7135500B2 (en) | 2002-11-15 | 2006-11-14 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Dihydroxymethylphenyl derivatives, processes for preparing them, and their use as pharmaceuticals |
US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
EP2281819A1 (de) | 2004-01-21 | 2011-02-09 | Novartis AG | Benzimidazol- oder Benzoxazol-derivate |
EP1911749A1 (de) | 2004-01-23 | 2008-04-16 | Boehringer Ingelheim International GmbH | Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel |
US7375104B2 (en) | 2004-01-23 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Long acting beta-2-agonists and their use as medicaments |
US7632834B2 (en) | 2004-01-23 | 2009-12-15 | Boehringer Ingelheim International Gmbh | Long acting beta-2-agonists and their use as medicaments |
WO2005070908A1 (de) * | 2004-01-23 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Neue lang wirksame beta-2-agonisten, und deren verwendung als arzneimittel |
US7160882B2 (en) | 2004-01-23 | 2007-01-09 | Boehringer Ingelheim International Gmbh | Long acting β-2-agonists and their use as medicaments |
US7405232B2 (en) | 2004-02-14 | 2008-07-29 | Boehringer Ingelheim International Gmbh | Long acting beta-2 agonists and their use as medicaments |
WO2005077361A1 (de) * | 2004-02-14 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel |
US7244728B2 (en) | 2004-03-17 | 2007-07-17 | Boehringer Ingelheim International Gmbh | Long acting betamimetics for the treatment of respiratory diseases |
WO2005092870A1 (de) * | 2004-03-17 | 2005-10-06 | Boehringer Ingelheim International Gmbh | Neue benzoxazinonderivate als langwirksame betamimetika zur behandlung von atemwegserkrankungen |
EP1577306A1 (de) * | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
JP2007529443A (ja) * | 2004-03-17 | 2007-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患を治療するために持続性ベータ受容体刺激剤模倣薬として使用される新規ベンゾオキサジノン誘導体 |
NO337714B1 (no) * | 2004-04-22 | 2016-06-06 | Boehringer Ingelheim Int | Medikamentkombinasjoner inneholdende benzoksaziner og anvendelse av slike til behandling av respiratoriske forstyrrelser |
EA012045B1 (ru) * | 2004-04-22 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Бензоксазины для лечения заболеваний дыхательных путей |
AU2005235420C1 (en) * | 2004-04-22 | 2011-02-24 | Boehringer Ingelheim International Gmbh | Benzoxazine for treating respiratory tract diseases |
EP2422786A1 (de) | 2004-04-22 | 2012-02-29 | Boehringer Ingelheim Pharma GmbH & Co. KG | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
EA013157B1 (ru) * | 2004-04-22 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей |
WO2005102350A1 (de) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Benzoxazine zur behandlung von atemwegserkrankungen |
AU2005235420B2 (en) * | 2004-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Benzoxazine for treating respiratory tract diseases |
WO2005102349A1 (de) | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
AU2005235419B2 (en) * | 2004-04-22 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
KR101287460B1 (ko) * | 2004-04-22 | 2013-07-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 벤즈옥사진을 함유하는 호흡기 질환 치료용 약제학적배합물 |
JP2007537187A (ja) * | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
WO2005111004A1 (de) * | 2004-05-14 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Neue langwirksame bronchodilatoren zur behandlung von atemwegserkrankungen |
US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
US8034809B2 (en) | 2004-05-14 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
EP3603634A1 (de) | 2004-05-18 | 2020-02-05 | Novartis AG | Pharmazeutische zusammensetzung enthaltend glykopyrrolat und einen beta2-adrenoceptor antagonisten |
EP2292619A1 (de) | 2004-10-22 | 2011-03-09 | Novartis AG | Purinderivate und ihre Verwendung als Adenosin A-2A Rezeptor Agonisten |
EP2206499A1 (de) | 2004-11-02 | 2010-07-14 | Novartis AG | Quinuclidinderivate und ihre verwendung als muscarinic m3 rezeptor antagonisten |
WO2006056471A1 (en) | 2004-11-29 | 2006-06-01 | Novartis Ag | 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity |
EP2305659A1 (de) | 2004-11-29 | 2011-04-06 | Novartis AG | 5-Hydroxy-Benzothiazol-Derivate mit der Aktivität von Beta-2-Adrenorezeptoragonisten |
US7423036B2 (en) | 2005-02-19 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Long-acting betamimetics for the treatment of respiratory complaints |
EP2253612A1 (de) | 2005-04-14 | 2010-11-24 | Novartis AG | Organische Verbindungen |
WO2006108643A2 (en) | 2005-04-14 | 2006-10-19 | Novartis Ag | Organic compounds |
EP2280006A1 (de) | 2005-08-08 | 2011-02-02 | Pulmagen Therapeutics (Synergy) Limited | Pharmazeutische zusammensetzung zum inhalieren enthaltend einen oxazol oder thiazol m3-muscarinrezeptor-antagonisten |
EP2281813A1 (de) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]Hept-7-Ylamin Derivate und deren Verwendung |
US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
EP1940349B1 (de) | 2005-10-10 | 2018-02-14 | Boehringer Ingelheim International GmbH | Aerosolformulierung für die inhalation von betaagonisten |
NO343363B1 (no) * | 2005-10-10 | 2019-02-11 | Boehringer Ingelheim Int | Medikamentformulering, anvendelse av medikamentformuleringen for fremstilling av et farmasøytisk preparat for behandling av respiratoriske sykdommer og inhalasjonssett inneholdende samme |
WO2007042468A3 (de) * | 2005-10-10 | 2007-08-02 | Boehringer Ingelheim Int | Aerosolformulierung für die inhalation von betaagonisten |
WO2007042468A2 (de) * | 2005-10-10 | 2007-04-19 | Boehringer Ingelheim International Gmbh | Aerosolformulierung für die inhalation von betaagonisten |
EP2532679A1 (de) | 2005-10-21 | 2012-12-12 | Novartis AG | Menschliche Antikörper gegen IL13 und therapeutische Verwendungen |
EP2532677A1 (de) | 2005-10-21 | 2012-12-12 | Novartis AG | Menschliche Antikörper gegen IL13 und therapeutische Verwendungen |
EP2286813A2 (de) | 2006-01-31 | 2011-02-23 | Novartis AG | Verwendung von Naphthyridin-Derivaten als Heilmittel |
WO2007121920A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
EP2322525A1 (de) | 2006-04-21 | 2011-05-18 | Novartis AG | Purinderivate als Adenosin A2A Rezeptoragonisten |
WO2008017638A1 (de) * | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel |
WO2008017637A1 (de) | 2006-08-07 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |
EP2279777A2 (de) | 2007-01-10 | 2011-02-02 | Irm Llc | Kanalaktivierende Proteasehemmer und deren Zusammensetzungen |
WO2008097673A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2332933A1 (de) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial Natrium-Kanal Inhibitoren |
EP2520574A1 (de) | 2007-12-10 | 2012-11-07 | Novartis AG | Am cyklischen Guanidin substituierte Amiloride Analoga als ENaC Blocker zur Behandlung von Atemwegserkrankungen |
EP2444120A1 (de) | 2007-12-10 | 2012-04-25 | Novartis AG | Spirocyclische Amiloride Analoga als ENac Blocker |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2009150137A2 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
US8815837B2 (en) | 2008-08-07 | 2014-08-26 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US9078885B2 (en) | 2008-08-07 | 2015-07-14 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
EP2813227A1 (de) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Zusammensetzungen für die Behandlung von Mukoviszidose und anderen chronischen Erkrankungen |
WO2011050325A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
WO2011051671A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Aminopyridine derivatives as kallikrein inhibitors |
WO2011051673A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Aminothiazole derivatives useful as klk1 inhibitors |
WO2011051672A1 (en) | 2009-10-28 | 2011-05-05 | Vantia Limited | Azaindole derivatives |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
WO2011098799A2 (en) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2011098801A1 (en) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Inflammatory disease treatment |
WO2011113894A1 (en) | 2010-03-19 | 2011-09-22 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf |
EP2845593A1 (de) | 2010-03-19 | 2015-03-11 | Novartis AG | Pyridin- und Pyrazinderivat zur Behandlung von chronisch obstruktiver Lungenerkrankung |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035158A1 (en) | 2010-09-17 | 2012-03-22 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2013030802A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013140319A1 (en) | 2012-03-19 | 2013-09-26 | Novartis Ag | Crystalline form of a succinate salt |
WO2014132220A1 (en) | 2013-03-01 | 2014-09-04 | Novartis Ag | Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162456A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
WO2021038426A1 (en) | 2019-08-28 | 2021-03-04 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
WO2021152488A1 (en) | 2020-01-29 | 2021-08-05 | Novartis Ag | Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody |
Also Published As
Publication number | Publication date |
---|---|
NO20025133D0 (no) | 2002-10-25 |
KR20020093083A (ko) | 2002-12-12 |
NZ522677A (en) | 2004-10-29 |
NO20025133L (no) | 2002-10-25 |
EA200201056A1 (ru) | 2003-04-24 |
CZ20023537A3 (cs) | 2003-02-12 |
BG107120A (en) | 2003-05-30 |
MXPA02010179A (es) | 2003-04-25 |
PL362868A1 (en) | 2004-11-02 |
IL152140A0 (en) | 2003-05-29 |
CN1426401A (zh) | 2003-06-25 |
JP2003533448A (ja) | 2003-11-11 |
EP1305300A1 (de) | 2003-05-02 |
SK15382002A3 (sk) | 2003-03-04 |
CA2405745A1 (en) | 2001-11-08 |
US20020022625A1 (en) | 2002-02-21 |
AR035637A1 (es) | 2004-06-23 |
BR0110331A (pt) | 2003-01-07 |
EE200200602A (et) | 2004-04-15 |
US20050137242A1 (en) | 2005-06-23 |
AU5629301A (en) | 2001-11-12 |
HRP20020845A2 (en) | 2003-10-31 |
HUP0300832A2 (hu) | 2003-08-28 |
YU79502A (sh) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001083462A1 (de) | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
DE10246374A1 (de) | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel | |
EP1328524B1 (de) | Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
EP1599478B1 (de) | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
EP1562892A1 (de) | Neue dihydroxy-methyl-phenyl-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
WO2005077361A1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
DE1643262C3 (de) | i-Phenoxy^-hydroxy-S-alklyaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP1761509A2 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
EP1706389A1 (de) | 3-hydroxymethyl-4-hydroxy-phenyl-derivate zur behandlung von atemwegserkrankungen | |
DE2502993A1 (de) | Amine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
DE10258695A1 (de) | Neuer, langwirksamer Beta-agonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel | |
EP0132811A1 (de) | In 1-Stellung substituierte 4-Hydroxymethyl-pyrrolidinone, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen und Zwischenprodukte | |
DE10051318A1 (de) | Neu, langwirksame Betamimetika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel | |
EP0000479B1 (de) | Substituierte 1-Piperazinyl-4H-s-triazolo (3,4-c)thieno(2,3-e)1,4-diazepine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
WO1992018480A1 (de) | 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung | |
AT329573B (de) | Verfahren zur herstellung von neuen thienodiazepinderivaten und ihren salzen | |
EP0273272B1 (de) | 17-Benzylspartein-Derivate enthaltende positiv inotrop wirksame pharmazeutische Zubereitungen | |
DE4019782A1 (de) | 9-amino-2-phenylbicyclo (3.3.1.) und 9-amino-2-phenylbicyclo (3.3.1.) non-2-ene und diese enthaltende therapeutische mittel | |
WO2003074469A1 (de) | Neue zimtsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
DE4216941A1 (de) | Para-substituierte Benzylamine und diese enthaltende therapeutische Mittel | |
DE4225353A1 (de) | Neue Pteridine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
DE19948428A1 (de) | Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel | |
EP1429751A1 (de) | Salicylsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
DE10216124A1 (de) | Neue Zimtsäuresalze, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel | |
ZA200208658B (en) | Novel, slow-acting betamimetics, a method for their production and their use as medicaments. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-795/02 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AU BG BR CA CN CO CZ EE HR HU ID IL IN JP KR LT LV MX NO NZ PL RO SG SI SK UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001929560 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2001 107120 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 152140 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405745 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010179 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01422/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-3537 Country of ref document: CZ Ref document number: P20020845A Country of ref document: HR |
|
ENP | Entry into the national phase |
Ref document number: 2001 580891 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/08658 Country of ref document: ZA Ref document number: 15382002 Country of ref document: SK Ref document number: 1020027014388 Country of ref document: KR Ref document number: 018086101 Country of ref document: CN Ref document number: 200208658 Country of ref document: ZA Ref document number: 02096990 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200979 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 56293/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200201056 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522677 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 20020779 Country of ref document: UZ Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014388 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3537 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001929560 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 522677 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 522677 Country of ref document: NZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-3537 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001929560 Country of ref document: EP |